FARALLON CAPITAL MANAGEMENT LLC - Q4 2020 holdings

$16.6 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 136 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 146.7% .

 Value Shares↓ Weighting
IQV BuyIQVIA HLDGS INC$724,475,000
+30.3%
4,043,506
+14.7%
4.36%
+13.3%
TMUS BuyT-MOBILE US INC$532,547,000
+28.0%
3,949,181
+8.6%
3.20%
+11.3%
TMO BuyTHERMO FISHER SCIENTIFIC INC$518,994,000
+7.3%
1,114,248
+1.7%
3.12%
-6.7%
SPY NewSPDR S&P 500 ETF TRput$510,346,0001,365,000
+100.0%
3.07%
V BuyVISA INC$487,353,000
+42.0%
2,228,104
+29.8%
2.93%
+23.4%
AON BuyAON PLC$479,903,000
+32.4%
2,271,514
+29.3%
2.89%
+15.2%
BSX BuyBOSTON SCIENTIFIC CORP$475,918,000
+50.5%
13,238,319
+60.0%
2.86%
+30.9%
ARMK NewARAMARK$424,202,00011,023,949
+100.0%
2.55%
MSFT BuyMICROSOFT CORP$391,052,000
+20.7%
1,758,168
+14.1%
2.35%
+4.9%
XLNX NewXILINX INC$362,364,0002,556,000
+100.0%
2.18%
ALXN NewALEXION PHARMACEUTICALS INC$351,056,0002,246,900
+100.0%
2.11%
RTX NewRAYTHEON TECHNOLOGIES CORP$324,820,0004,542,306
+100.0%
1.95%
CRM BuySALESFORCE COM INC$313,555,000
+78.7%
1,409,045
+101.8%
1.89%
+55.4%
IOVA BuyIOVANCE BIOTHERAPEUTICS INC$278,400,000
+42.0%
6,000,000
+0.8%
1.67%
+23.5%
AVGO NewBROADCOM INC$272,778,000622,995
+100.0%
1.64%
BX BuyBLACKSTONE GROUP INC$252,233,000
+26.2%
3,891,886
+1.6%
1.52%
+9.7%
EXEL BuyEXELIXIS INC$220,770,000
-16.0%
11,000,000
+2.3%
1.33%
-27.0%
WORK NewSLACK TECHNOLOGIES INC$207,496,0004,912,300
+100.0%
1.25%
WLTW BuyWILLIS TOWERS WATSON PLC LTD$202,780,000
+1842.2%
962,500
+1825.0%
1.22%
+1594.4%
IPHI NewINPHI CORP$198,951,0001,239,800
+100.0%
1.20%
BABA BuyALIBABA GROUP HLDG LTDsponsored ads$198,589,000
+10.3%
853,300
+39.3%
1.19%
-4.2%
HLT BuyHILTON WORLDWIDE HLDGS INC$182,515,000
+38.4%
1,640,437
+6.1%
1.10%
+20.4%
QGEN NewQIAGEN NV$172,120,0003,256,771
+100.0%
1.04%
MXIM BuyMAXIM INTEGRATED PRODS INC$136,734,000
+64.4%
1,542,400
+25.4%
0.82%
+43.0%
AMRS BuyAMYRIS INC$108,063,000
+164.3%
17,500,000
+25.0%
0.65%
+129.7%
BuyMOMO INCnote 1.250% 7/0$93,459,000
+13.2%
110,077,000
+5.8%
0.56%
-1.6%
LU NewLUFAX HOLDING LTD$76,080,0005,357,750
+100.0%
0.46%
BuyIQIYI INCnote 2.000% 4/0$71,760,000
+21.4%
81,762,000
+32.4%
0.43%
+5.6%
FGEN BuyFIBROGEN INC$70,471,000
-7.4%
1,900,000
+2.7%
0.42%
-19.4%
BCAB NewBIOATLA INC$66,900,0001,967,060
+100.0%
0.40%
GBIO BuyGENERATION BIO CO$64,321,000
-1.9%
2,268,819
+7.0%
0.39%
-14.6%
ARNA BuyARENA PHARMACEUTICALS INC$57,623,000
+22.3%
750,000
+19.1%
0.35%
+6.4%
CYTK BuyCYTOKINETICS INC$49,872,000
+7.1%
2,400,000
+11.6%
0.30%
-6.8%
CLGX BuyCORELOGIC INC$44,384,000
+90.1%
574,028
+66.4%
0.27%
+65.8%
IONS NewIONIS PHARMACEUTICALS INC$42,405,000750,000
+100.0%
0.26%
CARA BuyCARA THERAPEUTICS INC$37,295,000
+30.3%
2,465,000
+9.6%
0.22%
+13.1%
NewINSMED INCnote 1.750% 1/1$36,552,00032,500,000
+100.0%
0.22%
KRYS BuyKRYSTAL BIOTECH INC$31,500,000
+54.0%
525,000
+10.5%
0.19%
+34.0%
NVAX NewNOVAVAX INC$30,665,000275,000
+100.0%
0.18%
PANA NewPANACEA ACQUISITION CORPcl a$29,250,0002,500,000
+100.0%
0.18%
FOLD NewAMICUS THERAPEUTICS INC$28,863,0001,250,000
+100.0%
0.17%
CLVR NewCLEVER LEAVES HOLDINGS INC$28,730,0002,478,079
+100.0%
0.17%
BIIB NewBIOGEN INC$25,221,000103,000
+100.0%
0.15%
CNST NewCONSTELLATION PHARMCETICLS I$21,600,000750,000
+100.0%
0.13%
BEKE BuyKE HLDGS INCsponsored ads$21,108,000
+2.8%
343,000
+2.4%
0.13%
-10.6%
NewIQIYI INCnote 4.000%12/1$20,000,00020,000,000
+100.0%
0.12%
ZEAL BuyZEALAND PHARMA A/Ssponsored adr$18,329,000
-4.5%
510,000
+1.0%
0.11%
-17.3%
INBX BuyINHIBRX INC$16,815,000
+136.5%
510,000
+29.1%
0.10%
+106.1%
PRAX NewPRAXIS PRECISION MEDICINES I$13,755,000250,000
+100.0%
0.08%
NewNUANCE COMMUNICATIONS INCdbcv 1.000%12/1$13,052,0007,000,000
+100.0%
0.08%
XPO NewXPO LOGISTICS INC$13,112,000110,000
+100.0%
0.08%
NTLA NewINTELLIA THERAPEUTICS INC$12,240,000225,000
+100.0%
0.07%
TINVU NewTIGA ACQUISITION CORPunit 99/99/9999$11,426,0001,080,000
+100.0%
0.07%
RCKT NewROCKET PHARMACEUTICALS INC$10,968,000200,000
+100.0%
0.07%
CASU NewCASCADE ACQUISITION CORPunit 99/99/9999$10,346,000990,000
+100.0%
0.06%
KNTE NewKINNATE BIOPHARMA INC$9,945,000250,000
+100.0%
0.06%
ALBO BuyALBIREO PHARMA INC$9,378,000
+40.5%
250,000
+25.0%
0.06%
+21.7%
SURF NewSURFACE ONCOLOGY INC$9,240,0001,000,000
+100.0%
0.06%
NewGOSSAMER BIO INCnote 5.000% 6/0$9,032,00010,000,000
+100.0%
0.05%
ACIA BuyACACIA COMMUNICATIONS INC$7,296,000
+80.4%
100,000
+66.7%
0.04%
+57.1%
COGT NewCOGENT BIOSCIENCES INC$6,738,000600,000
+100.0%
0.04%
FPRX NewFIVE PRIME THERAPEUTICS INC$6,804,000400,000
+100.0%
0.04%
IMGN NewIMMUNOGEN INC$6,450,0001,000,000
+100.0%
0.04%
CRIS NewCURIS INC$5,938,000725,000
+100.0%
0.04%
MRVL NewMARVELL TECHNOLOGY GROUP LTDcall$5,943,000125,000
+100.0%
0.04%
STTK NewSHATTUCK LABS INC$5,241,000100,000
+100.0%
0.03%
TGTX NewTG THERAPEUTICS INC$5,202,000100,000
+100.0%
0.03%
HMCOU NewHUMANCO ACQUISITION CORPunit 12/08/2023$4,408,000400,000
+100.0%
0.03%
MASS New908 DEVICES INC$4,271,00075,000
+100.0%
0.03%
FDMT New4D MOLECULAR THERAPEUTICS IN$4,145,000100,000
+100.0%
0.02%
KURA NewKURA ONCOLOGY INC$4,083,000125,000
+100.0%
0.02%
NewISIS PHARMACEUTICALS INC DELnote 1.000%11/1$2,733,0002,500,000
+100.0%
0.02%
SBTX NewSILVERBACK THERAPEUTICS INC$2,207,00047,620
+100.0%
0.01%
CEREW NewCEREVEL THERAPEUTICS HLDNG I*w exp 06/09/202$758,000134,175
+100.0%
0.01%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2021-05-17
  • View 13F-HR/A filed 2021-08-13
  • View 13F-HR/A filed 2021-11-15
  • View 13F-HR filed 2021-02-16
  • View 13F-HR/A filed 2022-05-16
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MICROSOFT CORP41Q3 20233.7%
RADIUS HEALTH INC33Q2 20221.7%
GRIFOLS S A33Q4 20210.9%
ALPHABET INC32Q3 20234.2%
SPDR S&P 500 ETF TR31Q3 202325.3%
VISA INC30Q3 20232.9%
WABTEC CORP27Q3 20233.6%
EXELIXIS INC27Q3 20232.8%
ELEVANCE HEALTH INC26Q3 20232.6%
SAVARA INC26Q3 20230.3%

View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.

Latest significant ownerships (13-D/G)
FARALLON CAPITAL MANAGEMENT LLC Q4 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Atento S.A.March 15, 20232,230,35715.4%
Metals Acquisition CorpFebruary 07, 20232,489,7009.4%
Inflection Point Acquisition Corp.February 06, 20231,900,0005.8%
AMYRIS, INC.February 24, 20221,068,9040.3%
Swiftmerge Acquisition Corp.February 14, 2022291,0601.3%
Caribou Biosciences, Inc.February 11, 20222,428,1504.0%
ENANTA PHARMACEUTICALS INCFebruary 11, 2022287,0001.4%
Protagonist Therapeutics, IncFebruary 11, 2022387,0510.8%
Solid Power, Inc.February 11, 2022? ?
Better Therapeutics, Inc.February 09, 2022124,0650.5%

View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-14
13F-HR/A2024-02-14
13F-HR/A2024-02-14
13F-HR/A2024-02-14
13F-HR/A2024-02-14
13F-HR/A2024-02-14
13F-HR2024-02-14
13F-HR/A2024-02-12
SC 13G/A2024-02-01
SC 13G/A2024-01-23

View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been amended

Export FARALLON CAPITAL MANAGEMENT LLC's holdings